Drug intelligence / Profile preview

WT-9341

Development stage: Preclinical
Lead developer: WARF Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

WT-9341 is a preclinical-stage small molecule inhibitor developed by WARF Therapeutics for the treatment of prostate cancer. It is designed to target the androgen receptor (AR) and its splice variants (AR-Vs), which are frequently implicated in the development of resistance to standard androgen deprivation therapies in patients with castration-resistant prostate cancer (CRPC). Unlike many existing therapies that target the ligand-binding domain of the AR, this program focuses on inhibiting the activity of both full-length AR and truncated splice variants like AR-V7 that lack the ligand-binding domain but remain constitutively active.

Other names: Program 384Program384Program-384

Targets

E3 ligase (E3 ubiquitin ligases)NSD2 (Histone-lysine N-methyltransferase NSD2)

Beyond the preview

Go deeper on WT-9341.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-9341.

Explore the full profile